Mr Ian Murdoch
This presentation will discuss challenges presented by the glaucomas in the developed and in the developing world. Evidence to date suggests that a majority of the blindness from this disease group is potentially preventable for the duration of the patient’s life. What should a vision 2020 strategy be for the second most common cause of preventable blindness on the planet?
Taking two generic scenarios of developed and developing world, the current state of public percep-tion, case finding and management will be discussed. Some of our own work will be presented investigating interventions to attempt to improve matters. Finally some ideas for future direction will be presented for discussion.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY